###begin article-title 0
Mannose-binding lectin deficiency is associated with early onset of polyarticular juvenile rheumatoid arthritis: a cohort study
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
Mannose-binding lectin (MBL) is an innate immune protein. The aim of our study was to determine whether genetically determined MBL deficiency is associated with susceptibility to juvenile rheumatoid arthritis (JRA) and whether MBL2 genotypes are associated with JRA severity.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 544 549 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 600 602 598 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
In a retrospective cohort study of 218 patients with polyarthritis (n = 67) and oligoarthritis (n = 151), clinical and laboratory disease variables were obtained by clinical examination and chart reviews. Healthy Caucasian adults (n = 194) served as control individuals. MBL2 gene mutations were determined by Taqman analysis to identify genotypes with high, medium and low expression of MBL. Functional MBL plasma concentrations were measured using enzyme-linked immunosorbent assay. Associations between clinical and laboratory variables and MBL2 genotypes were determined by Kruskal-Wallis and chi2 tests.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 226 228 226 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 373 375 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 441 446 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 557 559 557 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 747 752 747 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
MBL2 genotype frequencies were similar in polyarthritis and oligoarthritis patients as compared with control individuals. MBL plasma concentrations were associated with the high, medium and low MBL genotype expression groups (P < 0.01). In polyarthritis patients, the presence of low-expressing (deficient) MBL2 genotypes was associated with early age at onset of disease (P = 0.03). In oligoarthritis patients, patients with low-expressing MBL2 genotypes were more often in remission (81%) than patients in the medium (54%) and high (56%) genotype groups (P = 0.02). The remaining clinical and laboratory variables, such as arthritis severity index, presence of radiographic erosions and antinuclear antibody positivity, were not associated with MBL2 genotypes.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 200 208 <span type="species:ncbi:9606">children</span>
Genetically determined MBL deficiency does not increase susceptibility to JRA, but MBL deficiency is associated with a younger age at onset of juvenile polyarthritis. On the other hand, MBL-deficient children with juvenile oligoarthritis are more often in remission. Therefore, MBL appears to play a dual role in JRA.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
Juvenile rheumatoid arthritis (JRA), also known as juvenile idiopathic arthritis (JIA), is a rheumatic disease of childhood, and includes a heterogeneous group of patients with differing characteristics, clinical manifestations, serological parameters and genetic background. Although the aetiology of JRA remains unknown, it appears to be a combined action of environmental, hormonal and genetic factors [1-3]. It is generally believed that infections play an important role in the pathogenesis of JRA [4].
###end p 11
###begin p 12
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 692 694 692 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B </italic>
###xml 709 711 709 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D </italic>
###xml 729 731 729 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 758 763 758 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 769 770 769 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 771 772 771 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 773 774 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 920 921 920 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 981 982 981 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1090 1092 1090 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H </italic>
###xml 1096 1098 1096 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L </italic>
###xml 1122 1124 1122 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X </italic>
###xml 1128 1130 1128 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y </italic>
###xml 1156 1158 1156 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1162 1164 1162 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q </italic>
###xml 1203 1208 1203 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 1214 1216 1214 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1217 1219 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1240 1241 1240 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 1242 1244 1242 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y </italic>
###xml 1284 1286 1284 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X </italic>
###xml 1348 1350 1348 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y </italic>
###xml 1486 1488 1486 1488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 1489 1492 1489 1492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA </italic>
###xml 1496 1498 1496 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 1499 1500 1499 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1591 1593 1591 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 1594 1596 1594 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 1600 1601 1600 1601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1602 1603 1602 1603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1622 1624 1622 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 1625 1628 1625 1628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA </italic>
###xml 1632 1634 1632 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 1635 1638 1635 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA </italic>
###xml 1730 1732 1730 1732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 1733 1736 1733 1736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA </italic>
###xml 1740 1742 1740 1742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 1743 1745 1743 1745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 1756 1758 1756 1758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 1759 1762 1759 1762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA </italic>
###xml 1766 1768 1766 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 1769 1770 1769 1770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1781 1783 1781 1783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 1784 1786 1784 1786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 1790 1791 1790 1791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1792 1793 1792 1793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1827 1829 1827 1829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1830 1832 1830 1832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1692 1700 <span type="species:ncbi:9606">patients</span>
Mannose-binding lectin (MBL) is a serum protein, produced in the liver, that plays an important role in innate immunity and functions as an opsonin, recognizing sugar structures on a wide variety of micro-organisms [5]. Serum MBL can directly opsonize micro-organisms and enhance the uptake by phagocytic cells via activation of the lectin pathway of the complement system [6,7]. Genetically determined functional MBL serum levels vary within the population. Six single nucleotide polymorphisms (SNPs) in the MBL2 gene on chromosome 10 are known to influence MBL plasma levels. Reduced or deficient MBL plasma levels are seen in individuals with heterozygous or homozygous SNPs in codons 54 (B mutation), 52 (D mutation), or 57 (C mutation) of exon 1 of the MBL2 gene [5,8,9]. The variant alleles occur with a combined phenotype frequency of about 25% to 30% in the Caucasian population [10,11]. The wild-type is called A, whereas the common designation for the variant alleles is O. In addition, MBL plasma concentrations fluctuate in the presence or absence of three SNPs (position -550: H and L alleles; position -221: X and Y alleles; and position +4: P and Q alleles) in the promoter region of the MBL2 gene [12,13]. However, only the X/Y variant has a pronounced influence; the X allele is associated with decreased plasma MBL levels and the Y variant with high plasma MBL levels. Subsequently, intermediately decreased MBL serum levels are seen in individuals with the genotypes XA/XA and YA/O, whereas very low or undetectable serum MBL levels are seen in individuals with genotypes XA/O and O/O. Individuals with YA/YA and YA/XA haplotypes have high or normal MBL levels. Therefore, patients can be classified into high (YA/YA and YA/XA), medium (XA/XA and YA/O) and low (XA/O and O/O) MBL genotype expression groups [10,14].
###end p 12
###begin p 13
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 902 907 902 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 1026 1031 1026 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 1104 1109 1104 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 110 118 <span type="species:ncbi:9606">children</span>
###xml 721 729 <span type="species:ncbi:9606">patients</span>
###xml 932 940 <span type="species:ncbi:9606">patients</span>
###xml 1155 1163 <span type="species:ncbi:9606">patients</span>
MBL deficiency has been associated with increased susceptibility to and severity of infections, especially in children [15,16]. In addition, it has been suggested that MBL modulates inflammation and autoimmune disease; for example, variant MBL alleles are risk factors for systemic lupus erythematosus [17,18]. It has also been suggested that MBL deficiency is associated with joint erosions and early disease onset of adult rheumatoid arthritis (RA) [19-23], although other investigators were unable to confirm such an association [24,25]. Moreover, it is believed that MBL plays an important role in innate immunity. Although unproven, it has been hypothesized that infection may trigger JRA in genetically susceptible patients [26]; this viewpoint suggests that MBL deficiency can predispose to JRA. In a recently reported study [27], there was no significant difference in genotypic frequencies of MBL2 codon 54 SNPs between 93 patients with JIA and 48 healthy control individuals. Codon 57 SNPs were not found. The other MBL2 SNPs were not investigated in this study. In addition, no association of MBL2 haplotypes was found between the subgroups of patients with JIA and control individuals.
###end p 13
###begin p 14
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 218 225 <span type="species:ncbi:9606">patient</span>
The aim of the present study was to determine whether genetically determined MBL deficiency is associated with susceptibility to JRA and whether MBL2 genotypes are associated with severity of JRA, as assessed based on patient characteristics and disease variables.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and samples
###end title 16
###begin p 17
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
###xml 79 87 <span type="species:ncbi:9606">children</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 486 494 <span type="species:ncbi:9606">Patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
###xml 929 937 <span type="species:ncbi:9606">patients</span>
Eligible patients participated in a larger cohort study of Caucasian Norwegian children with JRA and visited the Department of Rheumatology of Rikshospitalet University Hospital (Oslo, Norway) for the first time between January 1980 and September 1985 [28,29]. JRA was defined as meeting the American College of Rheumatology criteria for JRA [30]. The 236 patients from whom blood was drawn were stratified according to JRA subgroup, because disease variables vary within these groups. Patients with systemic arthritis (n = 2) and juvenile spondylarthropathy (juvenile ankylosing spondylitis [n = 3], seronegative enthesopathy [n = 4], juvenile psoriatic arthritis [n = 11], or inflammatory bowel disease associated arthritis [n = 1]) were excluded because these subgroups consisted of too few individuals to permit reliable statistic analysis. Of the 218 remaining patients, 151 had oligoarthritis and 67 had polyarthritis. The patients were examined and interviewed after a median disease duration of 14.8 years (interquartile range [IQR] 13.5 to 16.2 years) and their medical records were reviewed for variables associated with the onset and course of disease.
###end p 17
###begin p 18
###xml 647 649 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Plasma samples were immediately frozen at -80degreesC. Genomic DNA was isolated from heparinized/EDTA blood according to standard procedures. The study is compliant with the Helsinki Declaration. It was approved by the Regional Ethics Committee for Medical Research and written informed consent was given by the parents. Routine laboratory investigations included C-reactive protein (CRP) level and erythrocyte sedimentation rate, and detection of IgM-rheumatoid factor (RF) and antinuclear antibodies (ANAs). In addition, MBL plasma concentrations and genotypes were determined in 194 healthy adult volunteers, who served as control individuals [10].
###end p 18
###begin title 19
Clinical data
###end title 19
###begin p 20
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Demographic and clinical outcome variables were recorded from the charts at the follow-up visit. Onset of disease was defined as the date that arthritis was documented by a physician for the first time. The clinical examination included a physician's global assessment (PGA) of overall disease activity (ranging from 0 to 5) as well as assessment of numbers of actively involved (swollen or tender and mobility-restricted) and affected (swollen or mobility-restricted) joints, disease remission status (current remission, active disease after previous remission, or continuously active disease) and presence of uveitis. Furthermore, the number of cumulative affected joints and the arthritis severity index score were recorded. The Childhood Health Assessment Questionnaire (CHAQ) was used to measure physical disability at follow up [31]. It measures physical functioning in the following areas: dressing and grooming, arising, eating, walking, hygiene, reaching, gripping and activities. The mean CHAQ score ranges from 0 to 3, where 0 represents no disability and values above 1.5 represent severe disability.
###end p 20
###begin title 21
Radiographic examinations
###end title 21
###begin p 22
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 159 166 <span type="species:ncbi:9606">patient</span>
Radiographs of the sacroiliac joints, hips, ankles and tarsi were obtained at follow up of all patients, and examined by two radiologists, who were blinded to patient information and had no access to earlier radiographic, clinical, or laboratory data. Radiographs of other affected joints were obtained when clinically indicated. The radiographic changes were classified as joint erosions (grades III to V) or no joint erosions (grades 0 to II).
###end p 22
###begin title 23
MBL assays
###end title 23
###begin p 24
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 399 401 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 447 449 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 342 347 <span type="species:ncbi:10090">mouse</span>
###xml 353 358 <span type="species:ncbi:9606">human</span>
MBL measurements were performed at Sanquin Research and the Landsteiner Laboratory (Academic Medical Center, Amsterdam, The Netherlands). MBL plasma levels were measured using an enzyme-linked immunosorbent assay, as previously described [14,32]. Briefly, mannose was coated to the solid phase, and after incubation with plasma, biotinylated mouse-anti-human MBL IgG (10 mug/ml; Tacx and coworkers [32], Amsterdam) was used as detection antibody [32].
###end p 24
###begin p 25
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 427 429 427 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y </italic>
###xml 500 502 500 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 503 505 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 507 509 507 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 510 512 510 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 514 516 514 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 517 519 517 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 521 523 521 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 524 525 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 527 529 527 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 530 532 530 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 536 537 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 538 539 538 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 302 310 <span type="species:ncbi:9606">Patients</span>
Genotyping of the promoter polymorphisms and exon 1 SNPs was performed by allelic discrimination using a Taqman assay, using specific primers and minor groove binding probes for each SNP [14,33]. Genotyping was performed independently of the clinical data collection and MBL plasma level measurements. Patients were classified into three MBL2 genotype groups with high, medium and low expression of MBL. The influence of the X/Y allele was also determined by studying six 'extended' genotype groups: YA/YA, YA/XA, XA/XA, YA/O, XA/O and O/O.
###end p 25
###begin title 26
Statistical analysis
###end title 26
###begin p 27
###xml 278 280 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 408 413 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 561 563 559 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 744 749 742 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 612 620 <span type="species:ncbi:9606">Patients</span>
###xml 776 784 <span type="species:ncbi:9606">patients</span>
Data are presented as median and IQR because clinical and laboratory variables were not normally distributed. Consequently, the nonparametric Kruskal-Wallis and Mann-Whitney U tests were used for comparison of these variables. Frequencies between groups were compared by the chi2 or Fisher's exact test, where appropriate. Multivariate binominal logistic regression was used to study the association between MBL2 genotype and remission status (active/remission) after adjustment for disease duration. The odds ratio and 95% confidence interval were calculated. P < 0.05 was considered statistically significant. Patients were stratified according to remission status (active/remission) to explore further the association between CRP levels and MBL2 genotype in oligoarthritis patients. For statistical analysis SPSS 12.0.1 software was used (SPSS Inc., Chicago, IL, USA).
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
Demographics
###end title 29
###begin p 30
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 315 317 315 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 34 38 <span type="species:ncbi:9606">boys</span>
###xml 53 58 <span type="species:ncbi:9606">girls</span>
###xml 233 240 <span type="species:ncbi:9606">patient</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
The patient group consisted of 59 boys (27%) and 159 girls (73%), with a median age at diagnosis of 8.0 years (range 0.8 to 15.4 years; Table 1). The median (IQR) follow-up time was 14.8 (13.6 to 16.2) years. Table 1 shows that most patient characteristics differ between polyarthritis and oligoarthritis patients (P < 0.05). Therefore, the association between MBL2 genotype and disease was analyzed in the two JRA subsets separately (see below).
###end p 30
###begin p 31
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Demographic, clinical, and laboratory characteristics of JRA patients, according to disease onset subtype
###end p 31
###begin p 32
Continuous variables are presented as median (interquartile range [IQR]). JRA, juvenile rheumatoid arthritis.
###end p 32
###begin title 33
MBL genotype and functional MBL levels in relationship to disease
###end title 33
###begin p 34
###xml 119 120 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 122 124 121 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 128 130 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D </italic>
###xml 233 235 232 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 243 245 242 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 256 258 255 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 286 287 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 597 598 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 738 740 737 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 782 787 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 847 849 846 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 850 853 849 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA </italic>
###xml 873 875 872 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 876 879 875 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA </italic>
###xml 898 900 897 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 901 904 900 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA </italic>
###xml 924 926 923 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 927 929 926 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 949 951 948 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 952 954 951 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 975 976 974 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 977 979 976 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 1072 1074 1071 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1116 1118 1115 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1173 1175 1172 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA</italic>
###xml 1176 1179 1175 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YA </italic>
###xml 1215 1217 1214 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 1218 1220 1217 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 1224 1225 1223 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1226 1228 1225 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 1243 1244 1242 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1451 1453 1447 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1467 1468 1463 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1603 1605 1599 1601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
###xml 813 821 <span type="species:ncbi:9606">patients</span>
###xml 1254 1262 <span type="species:ncbi:9606">patients</span>
###xml 1593 1601 <span type="species:ncbi:9606">patients</span>
The median (range) MBL plasma concentration was 1.23 (0.01 to 7.59) mug/ml in the 218 JRA patients. Frequencies of the B, C and D exon 1 mutations in these JRA patients did not differ significantly from those in control individuals (P = 0.89, P = 1.00 and P = 0.37, respectively; Table 2). No deviation from Hardy-Weinberg equilibrium was observed in JRA patients or healthy control individuals (data not shown). Of the 218 JRA patients, 113 (52%) were in the high genotype expression group, 71 (33%) were in the medium genotype group and 34 (16%) were in the low genotype expression group (Table 2). The frequency of MBL deficiency was similar in JRA patients and control individuals (odds ratio 1.1, 95% confidence interval 0.9 to 1.4; P = 0.37). The distribution of the extended MBL2 haplotypes in the 218 JRA patients was as follows: 62 (28%) YA/YA haplotype, 51 (23%) YA/XA haplotype, 15 (7%) XA/XA haplotype, 56 (26%) YA/O haplotype, 25 (12%) XA/O haplotype and 9 (4%) O/O haplotype. These frequencies did not differ significantly from those in control individuals (P = 0.89) or between the two JRA subgroups (P = 0.69). MBL plasma concentrations were highest in the YA/YA genotype group and almost absent in XA/O and O/O groups (Figure 1). In JRA patients with high, medium and low expressing haplotypes, the median (IQR) MBL plasma level was 1.86 (1.23 to 3.26) mug/ml, 0.77 (0.38 to 1.41) mug/ml and 0.07 (0.04 to 0.15) mug/ml, respectively (P < 0.01; Table 2). The MBL plasma concentrations of the six extended genotype groups did not differ between polyarthritis and oligoarthritis patients (P > 0.46).
###end p 34
###begin p 35
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 236 238 236 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 357 359 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
MBL level according to (extended) MBL2 haplotypes in patients with juvenile polyarthritis and oligoarthritis. Median mannose-binding lectin (MBL) plasma levels, represented by horizontal lines, differ between extended haplotype groups (P < 0.01), but not between patients with oligoarthritis (n = 151) and polyarthritis (n = 67) who had similar haplotypes (P > 0.46).
###end p 35
###begin p 36
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
MBL concentrations and MBL2 genotypes
###end p 36
###begin p 37
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 537 539 537 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 555 557 555 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 591 593 591 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 643 645 643 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B </italic>
###xml 657 659 657 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 674 676 674 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D </italic>
###xml 20 28 <span type="species:ncbi:9606">children</span>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
Norwegian Caucasian children with juvenile polyarthritis (n = 67) and oligoarthritis (n = 151) are compared with 194 healthy Dutch Caucasian adult control individuals. Values are expressed as number (%) or, for continuous variables, as median (interquartile range). Median mannose-binding lectin (MBL) concentrations and frequencies of exon 1 mutations and MBL2 genotype groups did not differ between all juvenile rheumatoid arthritis (JRA) patients and healthy control individuals or within the polyarthritis and oligoarthritis groups (P values > 0.05). A is the designation for wild-type; O is the common designation for the variant alleles B (codon 54), C (codon 57) and D (codon 52).
###end p 37
###begin title 38
MBL association with disease parameters
###end title 38
###begin title 39
Polyarthritis group
###end title 39
###begin p 40
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 269 271 269 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 376 378 376 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 455 457 455 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 503 505 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 714 716 714 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1069 1070 1069 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1152 1153 1152 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1204 1206 1204 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1221 1222 1221 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1313 1314 1313 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1315 1316 1315 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1322 1323 1322 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1324 1326 1324 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 1334 1335 1334 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1336 1343 1336 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O MBL2 </italic>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
###xml 913 921 <span type="species:ncbi:9606">patients</span>
###xml 1295 1303 <span type="species:ncbi:9606">patients</span>
In the 67 patients with polyarthritis, patients in the low MBL2 genotype group were younger (4.4 years, IQR 3.6 to 7.0 years) at onset of disease than the patients in the medium (10.1 years, IQR 8.4 to 13.0 years) and high (9.5, IQR 5.6 to 13.0 years) genotype groups (P = 0.05; Table 3). This association was even stronger after exclusion of the 11 IgM-RF positive patients (P = 0.02; data not shown). The same association was found in the ANA-negative (P < 0.01) but not in the ANA-positive patients (P = 0.47; data not shown). In the high genotype expression group, four patients (11%) were IgM-RF positive, as compared with seven patients (30%) in the medium genotype group and none in the low genotype group (P = 0.06). We did not find any association of MBL genotype groups with other clinical features, such as number of cumulative affected joints, arthritis severity index, PGA, CHAQ scores, or number of patients with uveitis, remission, or severe radiographic erosions, or with laboratory tests such as ANAs, erythrocyte sedimentation rate, and IgM-RF (Table 3). CRP levels were similar in the high, medium and low MBL2 genotype group (Table 3), even after stratification for remission status (P > 0.10; Figure 2). No differences in clinical or laboratory variables were found between patients with the A/A, the A/O and the O/O MBL2 genotypes either (data not shown).
###end p 40
###begin p 41
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 457 459 457 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
CRP and MBL2 genotype: remission versus active disease. Shown are serum C-reactive protein (CRP) concentrations (mg/l) and mannose-binding lectin (MBL) genotype in patients with a current remission versus active disease (either active disease with a previous remission or continuously active disease). *Only CRP values of oligoarthritis patients with active disease (as compared with patients with a current remission) differed statistically significantly (P < 0.01).
###end p 41
###begin p 42
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
Association of demographic, clinical, and laboratory characteristics and MBL2 genotype expression groups: juvenile polyarthritis
###end p 42
###begin p 43
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Included in this analysis are 67 patients with juvenile polyarthritis. Values are expressed as number (%) or, for continuous variables, as median (interquartile range). aComparison of the high, medium and low genotype expression groups by means of the two-sided Fisher's exact test and Kruskal-Wallis test. bComparison of the high and medium genotype group versus the low genotype expression group by means of the two-sided Fisher's exact test and Mann-Whitney U-test. NS, not significant.
###end p 43
###begin title 44
Oligoarthritis group
###end title 44
###begin p 45
###xml 117 119 117 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 308 310 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 592 594 592 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 763 765 763 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 779 780 779 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 817 818 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 840 845 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 1379 1381 1379 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 137 145 <span type="species:ncbi:9606">Patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 858 866 <span type="species:ncbi:9606">patients</span>
###xml 896 904 <span type="species:ncbi:9606">patients</span>
###xml 972 980 <span type="species:ncbi:9606">patients</span>
###xml 1122 1130 <span type="species:ncbi:9606">patients</span>
###xml 1209 1217 <span type="species:ncbi:9606">patients</span>
In the 151 oligoarthritis patients, age at onset was similar in the high, medium and low genotype expression groups (P = 0.66; Table 4). Patients with oligoarthritis carrying the low MBL expression genotype were more often in remission (81%) than patients in the medium (54%) and high (56%) genotype groups (P = 0.02; Table 4). Multivariate analysis revealed that, after adjustment for disease duration, patients in the low genotype groups had an odds ratio of 2.5 (95% confidence interval 1.1 to 5.7) of being in remission at follow up, as compared with patients in the high genotype group (P = 0.04; data not shown). The median CRP level was 5 mg/l at follow up in the three genotype groups, but the CRP value distribution differed statistically significantly (P < 0.01; Table 4) between these three groups. Figure 2 shows CRP levels and MBL2 genotypes in patients with a current remission and patients with active disease with or without a previous remission. When the patients were stratified according to remission status (remission versus active), median CRP levels remained statistically significantly different in patients with active disease as compared with those with a current remission. In these patients, the median (IQR) CRP level was 4 (1 to 5) mg/l in the high genotype group versus 5 (4 to 10) mg/l in the medium and 5 (5 to 9) mg/l in the low genotype groups (P < 0.01).
###end p 45
###begin p 46
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
Association of demographic, clinical, and laboratory characteristics and MBL2 genotype expression groups: oligoarthritis
###end p 46
###begin p 47
###xml 171 172 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 309 310 309 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Included in this analysis are 151 patients with juvenile oligoarthritis. Values are expressed as number (%) or, for continuous variables, as median (interquartile range). aComparison of the high, medium and low genotype expression groups by means of the two-sided Fisher's exact test and Kruskal-Wallis test. bComparison of the high and medium genotype group versus the low genotype expression group by means of the two-sided Fisher's exact test and Mann-Whitney U-test. NS, not significant.
###end p 47
###begin p 48
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 250 252 250 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O </italic>
###xml 260 261 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 262 269 262 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O MBL2 </italic>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
The remaining clinical and laboratory variables did not differ between the patients in the high, medium and low MBL2 genotype groups (Table 4). The differences found in CRP level and remission status were also present in patients with the A/A, the A/O and the O/O MBL2 genotype. Other clinical and laboratory variables did not differ between these patients (data not shown).
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 453 458 453 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 112 120 <span type="species:ncbi:9606">children</span>
###xml 275 283 <span type="species:ncbi:9606">patients</span>
In this study we demonstrated that the frequency of MBL deficiency was not increased in 218 Norwegian Caucasian children with JRA as compared with 194 Dutch Caucasian control individuals. Our observations are in agreement with the only previous study of MBL conducted in JIA patients [27]. In that study no association between MBL2 codon 54 mutations and JIA was found. We have now shown that JRA is also not associated with any of the other five known MBL2 SNPs.
###end p 50
###begin p 51
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
The frequency of these mutations also did not differ from the frequencies identified in previously published Danish Caucasian control populations [10,11]. Over the past few years studies have been published that consistently reported similar frequencies in Caucasian populations of different countries [10,11,34]. Therefore, we assume that the frequencies of MBL2 gene polymorphism in the Caucasian Norwegian population do not differ from those in other Caucasian populations. Therefore, our present observations suggest that genetically determined MBL deficiency is not associated with increased susceptibility to JRA. Based on the number of included patients and control individuals, this study has 80% power when an odds ratio of 1.71 or greater for MBL deficiency is found.
###end p 51
###begin p 52
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1271 1273 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1274 1276 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1415 1417 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 15 23 <span type="species:ncbi:9606">children</span>
###xml 105 113 <span type="species:ncbi:9606">children</span>
###xml 1405 1413 <span type="species:ncbi:9606">patients</span>
Interestingly, children in the low MBL2 genotype group developed polyarthritis at a younger age than did children in the medium or high genotype groups. Previously, Garred and coworkers [23] showed that MBL2 exon 1 variant allele carrier status was associated with early age at onset of RA, which is the adult counterpart of polyarthritis [26]. Garred and coworkers hypothesized that MBL may delay the onset of RA but that it does not prevent the disease. The mechanism by which MBL deficiency might promote inflammation in immune-mediated inflammatory diseases such as RA and JRA is as yet unknown. MBL deficiency might lead to a diminished innate immunity, and subsequent increased risk for infections, as was previously remonstrated [15,16]. These infections may trigger JRA, as has been hypothesized previously [26]. Another possibility is that MBL is involved in the recognition of an infectious agent in the pathophysiology of JRA. Low or absent MBL plasma concentration leads to decreased complement activation and ineffective clearance of the pathogen or pathogen-derived antigens. The prolonged presence of infectious agents in the host may enhance synovial inflammation because of the proinflammatory effects of bacterial DNA and bacterial cell wall fragments [35,36]. Anti-MBL autoantibodies may also play a role, because elevated levels of anti-MBL autoantibodies were found in the sera of RA patients [37]. It is unclear at present whether MBL deficiency is indeed involved in the pathogenesis of RA or JRA, because the data reported are variable.
###end p 52
###begin p 53
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
Furthermore, MBL deficiency does not appear to play a role once polyarthritis has developed, because no associations were found between MBL2 genotype and the laboratory variables or the remaining disease severity related clinical variables, such as PGA, CHAQ score, number of actively involved or affected joints, and number of patients with uveitis or remission. Consistent with the previous report by Barton and coworkers [25] on RA and MBL polymorphisms, we did not find an association between erosive joint destruction and MBL polymorphisms in patients with JRA.
###end p 53
###begin p 54
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1053 1055 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1364 1366 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1367 1369 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1785 1790 1785 1790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 113 121 <span type="species:ncbi:9606">children</span>
###xml 933 941 <span type="species:ncbi:9606">patients</span>
###xml 955 963 <span type="species:ncbi:9606">patients</span>
###xml 1673 1681 <span type="species:ncbi:9606">children</span>
###xml 1802 1810 <span type="species:ncbi:9606">patients</span>
In the oligoarthritis group, patients in the low genotype group were in remission more often (81%) than were the children in the medium or high genotype group (54% to 56%). In this regard, lack of the protein MBL in serum appears to be associated with a milder disease course or decreased inflammation. The possible explanation for these findings might be that MBL has an immunomodulating effect. MBL is present in synovial fluid and can bind potential causative agents in JRA including micro-organisms, cellular debris, and agalactosyl IgG (IgG-G0) [38,39]. Binding of MBL to agalactosyl IgG immune complexes may result in local complement activation and subsequent increased inflammation and thus active disease, whereas this is absent in the presence of very low levels of MBL [40]. Recently, Troelsen and colleagues [41] found that high serum levels of MBL and agalactosyl IgG were risk factors for ischaemic heart disease in RA patients. Besides, RA patients had higher MBL levels than did their relatives, suggesting that high MBL may trigger RA [39]. Harmful effects of high MBL levels have been shown in other disease entities as well. For instance, MBL deposits in the glomeruli can cause histological damage of kidneys, and activation of the lectin pathway by MBL can induce vascular tissue damage in myocardial ischemia-reperfusion injury and diabetes [42-44]. On the other hand, MBL deficiency might be associated with defective clearance of immune complexes and apoptotic cells, as seen in individuals with C1q deficiency. Because MBL and C1q are molecules with similar characteristics this might explain why during active disease CRP levels were increased in children in the low compared with the medium and high genotype groups. Remission rates were not associated with MBL2 genotype in patients with polyarthritis, possibly because more joints were affected.
###end p 54
###begin title 55
Conclusion
###end title 55
###begin p 56
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBL2 </italic>
###xml 191 199 <span type="species:ncbi:9606">children</span>
MBL appears to play a dual role in JRA. Genetically determined MBL deficiency does not increase susceptibility to JRA, but MBL does appear to have an immunomodulating effect. On the one hand children with low levels of MBL develop polyarthritis at younger age. In the case of MBL deficiency, potential explanations for this younger age at onset are increased susceptibility to infections, as a potential trigger of polyarthritis, or ineffective clearance of infectious agents in the pathophysiology of JRA. On the other hand, the low MBL2 expressing genotypes appear to be beneficial once oligoarthritis has developed, because they are associated with increased frequency of remission. An explanation may be that the local MBL itself may lead to complement-mediated inflammation in the synovium, sustaining active disease. If we are to discover the possible contribution of MBL to JRA disease severity, then we must study molecular mechanisms such as the interaction of MBL with immune complexes, the presence of anti-MBL autoantibodies and the role of activation of the complement system.
###end p 56
###begin title 57
Abbreviations
###end title 57
###begin p 58
ANA = antinuclear antibody; CHAQ = Childhood Health Assessment Questionnaire; CRP = C-reactive protein; IQR = interquartile range; MBL = mannose-binding lectin; JIA = juvenile idiopathic arthritis; JRA = juvenile rheumatoid arthritis; PGA = physician's global assessment; RA = rheumatoid arthritis; RF = rheumatoid factor; SNP = single nucleotide polymorphism.
###end p 58
###begin title 59
Competing interests
###end title 59
###begin p 60
The authors declare that they have no competing interests.
###end p 60
###begin title 61
Authors' contributions
###end title 61
###begin p 62
The study was designed by KD, TK, PT and AS. They were all involved in the management of the study and in supporting other contributors. BF, OF and AS collected the clinical data. NB conducted the laboratory investigations. FF analyzed the data statistically and interpreted the results. She completed the first draft, written by KD. Finally, each author contributed to the writing of the final manuscript. They all read and approved this version of the manuscript and take full responsibility for it.
###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
We thank Professor Ben Dijkmans for his intermediary support and Michel van Houdt for excellent technical assistance.
###end p 64
###begin article-title 65
The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis
###end article-title 65
###begin article-title 66
HLA class II alleles and heterogeneity of juvenile rheumatoid arthritis. DRB1*0101 may define a novel subset of the disease
###end article-title 66
###begin article-title 67
Pauciarticular arthritis of childhood (pauciarticular juvenile rheumatoid arthritis)
###end article-title 67
###begin article-title 68
Do infectious agents cause rheumatoid arthritis?
###end article-title 68
###begin article-title 69
Mannose-binding lectin: the pluripotent molecule of the innate immune system
###end article-title 69
###begin article-title 70
Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition
###end article-title 70
###begin article-title 71
###xml 63 98 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1
###end article-title 71
###begin article-title 72
High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene
###end article-title 72
###begin article-title 73
###xml 80 85 <span type="species:ncbi:9606">human</span>
A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein
###end article-title 73
###begin article-title 74
Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop
###end article-title 74
###begin article-title 75
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Variant mannose-binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in randomly included patients
###end article-title 75
###begin article-title 76
Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein
###end article-title 76
###begin article-title 77
Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America
###end article-title 77
###begin article-title 78
###xml 64 72 <span type="species:ncbi:9606">patients</span>
The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia
###end article-title 78
###begin article-title 79
Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood
###end article-title 79
###begin article-title 80
Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series
###end article-title 80
###begin article-title 81
Mannose-binding lectin deficiency - revisited
###end article-title 81
###begin article-title 82
The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis
###end article-title 82
###begin article-title 83
Mannan binding lectin in rheumatoid arthritis. A longitudinal study
###end article-title 83
###begin article-title 84
The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis
###end article-title 84
###begin article-title 85
The influence of mannose binding lectin polymorphisms on disease outcome in early polyarthritis. TIRA Group
###end article-title 85
###begin article-title 86
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Low mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A prospective study
###end article-title 86
###begin article-title 87
Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study
###end article-title 87
###begin article-title 88
Absence of an association between mannose-binding lectin polymorphism and rheumatoid arthritis
###end article-title 88
###begin article-title 89
Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis
###end article-title 89
###begin article-title 90
Juvenile idiopathic arthritis
###end article-title 90
###begin article-title 91
Lack of association between mannose-binding lectin gene polymorphisms and juvenile idiopathic arthritis in a Han population from the Hubei province of China
###end article-title 91
###begin article-title 92
###xml 17 24 <span type="species:ncbi:9606">patient</span>
The influence of patient characteristics, disease variables, and HLA alleles on the development of radiographically evident sacroiliitis in juvenile idiopathic arthritis
###end article-title 92
###begin article-title 93
Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years
###end article-title 93
###begin article-title 94
Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation
###end article-title 94
###begin article-title 95
###xml 32 40 <span type="species:ncbi:9606">children</span>
Measurement of health status in children with juvenile rheumatoid arthritis
###end article-title 95
###begin article-title 96
Mannan binding lectin in febrile adults: no correlation with microbial infection and complement activation
###end article-title 96
###begin article-title 97
An analysis of genetic variation across the MBL2 locus in Dutch Caucasians indicates that 3' haplotypes could modify circulating levels of mannose-binding lectin
###end article-title 97
###begin article-title 98
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Influence of mannose-binding lectin on HIV infection and tuberculosis in a Western-European population
###end article-title 98
###begin article-title 99
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines
###end article-title 99
###begin article-title 100
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides
###end article-title 100
###begin article-title 101
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance
###end article-title 101
###begin article-title 102
The potential role of mannan-binding lectin in the clearance of self-components including immune complexes
###end article-title 102
###begin article-title 103
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with rheumatoid arthritis have higher levels of mannan-binding lectin than their first-degree relatives and unrelated controls
###end article-title 103
###begin article-title 104
Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein
###end article-title 104
###begin article-title 105
Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis
###end article-title 105
###begin article-title 106
###xml 67 72 <span type="species:ncbi:9606">human</span>
Functional characterization of the lectin pathway of complement in human serum
###end article-title 106
###begin article-title 107
Association between mannose-binding lectin and vascular complications in type 1 diabetes
###end article-title 107
###begin article-title 108
Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury
###end article-title 108

